New Delhi, Feb 20 (IANS) A team of scientists from the Institute of Nano Science and Technology (INST), Mohali — an autonomous institute of the Department of Science and Technology (DST) — has identified some common metabolites of hard to detect pancreatic and glioma cancers, which can boost their early diagnosis and lead to better treatment outcomes.
The team identified metabolites in exosomes derived from pancreatic cancer, lung cancer and glioma cancer cell line, which offers potential universal biomarkers resulting in enhanced clinical applicability.
“This offers a potential non-invasive method for early cancer diagnosis as well as therapeutic strategies for cancer,” said the researchers in the paper, published in the journal Nanoscale.
Aggressive cancers like pancreatic and glioma cancers often diagnosed late and having poor prognoses. Hence there is an urgent need for non-invasive, reliable cancer biomarkers to address significant gaps in cancer diagnostics and therapeutics, particularly for pancreatic and glioma cancers, which lack early detection methods.
Nano messengers (exosomes) — as carriers of tumour-derived metabolites — provide a unique opportunity to explore the tumour microenvironment (TME), said the team, including Nandini Bajaj and Dr. Deepika Sharma from the Institute.
The researchers utilised a multi-technique approach combining Nanoparticle Tracking Analysis (NTA), Electron Microscopy (EM), Western Blot (WB), Fourier Transformed Infrared Spectroscopy (FTIR), untargeted Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), and Nuclear Magnetic Resonance (NMR) — providing a comprehensive characterisation of exosomes, surpassing conventional single-method studies.
The study advances cancer diagnostics, personalised medicine, and our understanding of cancer progression mechanisms. These metabolites identified highlight dysregulated pathways in the tumour microenvironment and also gives insights on how the cancer progresses and enables non-invasive and precise cancer detection and therapeutic targeting.
The findings can lead to the development of targeted therapies that can disrupt dysregulated metabolic pathways in tumours, enhancing treatment efficacy and potentially reducing side effects.
This advancement could significantly improve patient outcomes, especially through personalised, precision medicine approaches.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
